SCHEMBL6006413

SCHEMBL6006413

[NH]CCNS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.64
SCN1A P35498 2/20 0.64
SCN2A Q99250 2/20 0.64
SCN3A Q9NY46 2/20 0.64
KDM4E B2RXH2 2/20 0.64
CYP1A2 P05177 2/20 0.64
CYP2C9 P11712 2/20 0.64
CYP2C19 P33261 2/20 0.64
HSD17B10 Q99714 2/20 0.64
ALDH1A1 P00352 1/20 0.64
NPY5R Q15761 4/20 0.53
CYP2D6 P10635 3/20 0.50
MEN1 O00255 2/20 0.50
PRKD3 O94806 2/20 0.50
PRKCG P05129 2/20 0.50
PRKCB P05771 2/20 0.50
PRKCA P17252 2/20 0.50
NFKB1 P19838 2/20 0.50
PRKCH P24723 2/20 0.50
PRKCI P41743 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6006630 0.86 SCN1A (0.59) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL607517 0.85 CYP3A4 (0.66) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL4263470 0.83 CYP3A4 (0.78) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL3680789 0.83 CYP3A4 (0.64) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL11176407 0.83 CYP3A4 (0.64) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL607518 0.83 CYP3A4 (0.64) CYP3A4SCN1ASCN2ASCN3AKDM4E
Hydrochloric Acid SCHEMBL29141926 0.82 SCN1A (0.78) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL6006634 0.81 CYP3A4 (0.69) CYP3A4SCN1ASCN2ASCN3AKDM4E
Hydrochloric Acid SCHEMBL30639783 0.81 LMNA (0.71) CYP3A4SCN1ASCN2ASCN3AKDM4E
SCHEMBL3701345 0.81 NSD2 (0.72) CYP3A4SCN1ASCN2ASCN3AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 CYP3A4 313/4885SCN1A 868/4885SCN2A 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.